Form 4: Shattuck Labs Director Amy Kate Sasser Acquires Stock Options
SEC Form 4 Filing
Director Amy Kate Sasser acquired options to purchase 33,409 shares of Shattuck Labs common stock on March 6, 2024.
Summary
- Amy Kate Sasser, a director of Shattuck Labs, Inc., acquired stock options on March 6, 2024.
- The options grant the right to purchase 33,409 shares of Shattuck Labs common stock at an exercise price of $9.47 per share.
- The options vest in three equal annual installments starting on March 1, 2025, contingent upon Sasser's continued service to the company.
- The options expire on March 6, 2034.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a standard executive compensation practice.
Positives
- The acquisition of stock options by a director signals confidence in the company's future performance.
Future Outlook
The vesting schedule of the options incentivizes the director to remain with the company for at least three years.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially driving long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 03/01/2024 | First vesting date for the stock options. |
| 03/06/2024 | Date of the stock option grant. |
| 03/08/2024 | Date of the Form 4 filing. |
| 03/06/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.